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background: We aimed to investigate bare metal stents (BMS) post-dilated with paclitaxel-eluting balloons (DEB) and hypothesized sufficient 
stent coverage after 6 months and prevention of target-lesion restenosis (TLR).
methods: In this randomized trial (NCT01056744) 105 lesions in 90 patients were randomly treated with either BMS + DEB post-dilation (n = 54) 
or with the XIENCE V® DES (n = 51), and evaluated at 6-month f/u with optical coherence tomography (OCT). 2yr clinical f/u was done using the 
hospital information system and by telephone.
results: 3D-OCT analysis showed significantly more global neointimal proliferation in the BMS + DEB group (15.7 ± 7.8 vs. 11.0 ± 5.2 mm³ 
proliferation volume/cm, p = 0.001). No differences regarding focal in-stent stenosis analyzed with angiography (% stenosis at 6-months: 17.2 ± 
10.3 vs. 23.4 ± 12.0, n.s.) and OCT were found (peak local area stenosis: 36.8 ± 15.6 % vs. 39.5 ± 13.8 %, n.s.). Dual antiplatelet therapy was 
discontinued in all patients after 6 months due to a sufficient stent coverage > 94 % in OCT (% uncovered struts 5.0 ± 9.4 % in DES vs. 5.6 ± 9.6 % 
in BMS + DEB, n.s.). Major adverse cardiac events (myocardial infarction, revascularization, death) after 6 and 24 months did not differ between the 
two device groups (Table 1). />
conclusions: The combined BMS + DEB procedure effectively prevented in-stent restenosis in this trial with a non-inferior long-term cardiovascular 
outcome compared to XIENCE V DES. Discontinuation of clopidogrel after six months was safe.
 
